Standout Papers
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer (2011)
- KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer (2006)
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab (2008)
- Analysis of PTEN , BRAF , and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer (2009)
- Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features (2018)
Immediate Impact
3 by Nobel laureates 4 from Science/Nature 158 standout
Citing Papers
Pancreatic cancer
2025 Standout
Computational design of soluble and functional membrane protein analogues
2024 StandoutNatureNobel
Works of Jean‐Baptiste Bachet being referenced
Panitumumab‐based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials
2019
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Jean‐Baptiste Bachet | 11132 | 4076 | 3989 | 210 | 13.2k | |
| Antoine Adenis | 10134 | 5225 | 2882 | 212 | 13.8k | |
| Jean‐Luc Van Laethem | 7704 | 3103 | 2154 | 275 | 10.1k | |
| Christelle de la Fouchardière | 7592 | 2726 | 2666 | 188 | 10.4k | |
| Eric Assénat | 6994 | 2391 | 2619 | 171 | 9.9k | |
| Joon Oh Park | 9002 | 7439 | 2818 | 378 | 15.8k | |
| Rosine Guimbaud | 7517 | 2452 | 2328 | 177 | 9.3k | |
| Milind Javle | 7208 | 3782 | 2237 | 388 | 11.5k | |
| Gabriella Fontanini | 7116 | 4574 | 2690 | 312 | 13.2k | |
| Won Ki Kang | 5792 | 5912 | 1836 | 344 | 11.8k | |
| Antoine Hollebecque | 6269 | 2951 | 1471 | 308 | 10.8k |
All Works
Login with ORCID to disown or claim papers
Loading papers...